PROSCA/BLADDR 2022 | MCED: reducing cancer mortality

In the United States, more than 600,000 people a year die of cancer. Eric Klein, MD, Glickman Urology & Kidney Institute, Cleveland, OH, discusses the role of multi-cancer early detection (MCED) in cancer screening to reduce cancer mortality. MCED utilizes next-generation sequencing to detect cancer-associated circulating cell-free DNA, which has been validated to detect over 50 cancer types. This interview took place at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR 2022) in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.